NASDAQ:ARLZ Aralez Pharmaceuticals (ARLZ) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free ARLZ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range N/A52-Week Range$0.02▼$2.98VolumeN/AAverage Volume5.13 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aralez Pharmaceuticals alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Aralez Pharmaceuticals Stock (NASDAQ:ARLZ)Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> ARLZ Stock News HeadlinesMay 25, 2024 | benzinga.comAdrian Adams's Net WorthFebruary 29, 2024 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (AMRX)September 11, 2023 | forbes.comAveo PharmaceuticalsAugust 16, 2023 | uk.investing.comMGC Pharmaceuticals Ltd (MXCM)March 1, 2022 | prnewswire.comMIT's Golub Center for Finance and Policy opens nomination period for the second biennial Miriam Pozen Prize, recognizing outstanding contributions to financial policySee More Headlines Receive ARLZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aralez Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2017Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARLZ CUSIP73941U10 CIK1660719 Webwww.aralez.com Phone905-876-1118FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Adrian Adams (Age 67)CEO & Director Mr. Andrew I. Koven (Age 60)Pres & Chief Bus. Officer Mr. Michael Kaseta (Age 42)Chief Financial Officer Dr. James Patrick Tursi (Age 53)Chief Medical Officer Mr. John E. Barnhardt CPA (Age 68)Principal Accounting Officer and VP of Fin. & Admin. Key CompetitorsEli Lilly and CompanyNYSE:LLYJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVPfizerNYSE:PFEView All Competitors ARLZ Stock Analysis - Frequently Asked Questions How were Aralez Pharmaceuticals' earnings last quarter? Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced its quarterly earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. The firm earned $24.30 million during the quarter, compared to the consensus estimate of $22.87 million. Aralez Pharmaceuticals's revenue was up 78.7% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS. What other stocks do shareholders of Aralez Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aralez Pharmaceuticals investors own include Magnegas Applied Tchnlgy Sltns (MNGA), RedHill Biopharma (RDHL), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Liquidmetal Technologies (LQMT), Taiwan Semiconductor Manufacturing (TSM) and Advanced Micro Devices (AMD). This page (NASDAQ:ARLZ) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aralez Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aralez Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.